Phase II evaluation of oral idarubicin (4-demethoxydaunorubicin) in patients with disseminated malignant melanoma.

Bonaventura Lazzaro(Tumori Foundation), Paola Papaldo(Cancer Institute (WIA)), Nicola Di Pietro, Luigi Di Lauro, Fabrizio Ganzina(Ospedale San Carlo)

PubMed

July 1, 1986

Cited by 6

Related Papers

Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial

|The Lancet|2015|202

Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial. Italian Multicentre Breast Study with Epirubicin.

|Journal of Clinical Oncology|1988|168

Lonidamine: Efficacy and safety in clinical trials for thetreatment of solid tumors

|Drugs of today|2003|168

Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine

|Annals of Oncology|2010|168

Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer

|Breast Cancer Research and Treatment|2006|140